Skip to main content
Nature Communications logoLink to Nature Communications
. 2021 May 5;12:2708. doi: 10.1038/s41467-021-23082-3

Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

Sho Iketani 1,2, Farhad Forouhar 3, Hengrui Liu 4, Seo Jung Hong 5, Fang-Yu Lin 6, Manoj S Nair 1, Arie Zask 7, Yaoxing Huang 1, Li Xing 6, Brent R Stockwell 4,7,, Alejandro Chavez 5,, David D Ho 1,2,
PMCID: PMC8098641  PMID: 33953192

Correction to: Nature Communications 10.1038/s41467-021-22362-2, published online 1 April 2021.

The original version of this Article omitted the following from the Acknowledgements: Part of the research was conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences from the National Institutes of Health (P30 GM124165). This has now been corrected in both the PDF and HTML versions of the Article.

Contributor Information

Brent R. Stockwell, Email: bstockwell@columbia.edu

Alejandro Chavez, Email: ac4304@cumc.columbia.edu.

David D. Ho, Email: dh2994@cumc.columbia.edu


Articles from Nature Communications are provided here courtesy of Nature Publishing Group

RESOURCES